(NASDAQ: IBIO) Ibio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.
Ibio's earnings in 2026 is -$20,108,000.On average, 6 Wall Street analysts forecast IBIO's earnings for 2026 to be -$7,971,751, with the lowest IBIO earnings forecast at -$10,357,654, and the highest IBIO earnings forecast at -$6,611,269. On average, 5 Wall Street analysts forecast IBIO's earnings for 2027 to be -$6,804,659, with the lowest IBIO earnings forecast at -$8,374,273, and the highest IBIO earnings forecast at -$4,250,101.
In 2028, IBIO is forecast to generate -$7,913,284 in earnings, with the lowest earnings forecast at -$10,578,030 and the highest earnings forecast at -$4,958,451.